You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百利天恒(688506.SH):全資子公司SystImmune與百時美施貴寶就BL-B01D1的開發和商業化權益達成全球戰略合作協議

格隆匯12月12日丨百利天恒(688506.SH)公佈,2023年12月11日,公司全資子公司SystImmune,Inc.(以下簡稱"SystImmune")與百時美施貴寶(以下簡稱"BMS",紐交所代碼:BMY)就BL-B01D1(EGFR×HER3雙抗ADC)項目達成獨家許可與合作協議(以下簡稱"合作協議")。BL-B01D1是一款潛在的同類首創EGFR/HER3雙特異性抗體藥物偶聯物(ADC)。

根據合作協議,雙方將合作推動BL-B01D1在美國的開發和商業化。SystImmune將通過其關聯公司獨家負責BL-B01D1在中國大陸的開發、商業化以及在中國大陸的生產,並負責生產部分供中國大陸以外地區使用的藥品。BMS將獨家負責BL-B01D1在全球其他地區的開發和商業化。合作協議生效後,BMS將向SystImmune支付8億美元的首付款,和最高可達5億美元的近期或有付款;達成開發、註冊和銷售里程碑後,SystImmune將獲得最高可達71億美元的額外付款;潛在總交易額最高可達84億美元。合作協議中所約定的里程碑付款需要滿足一定的條件,最終里程碑付款尚存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account